Lung Cancer
News
First drug for MET+ NSCLC shows high response rates
Among patients with a MET exon 14 skipping mutation, capmatinib produced a response in 41% of previously treated patients and 68% of treatment-...
Original Research
Thromboembolic Events in Lung Cancer Patients Treated With Conventional Chemotherapy Alone Compared With Immunotherapy
Clinical Review
A Case of Alectinib Cutaneous Toxicity and Results of a Desensitization Protocol
News
Immunotherapy should not be withheld because of sex, age, or PS
News
Aspirin may accelerate cancer progression in older adults
News
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
A survey finds the COVID-19 pandemic to have a significant impact on oncologists’ decision-making.
News
NSCLC success story: Mortality down, survival improved
In recent years, mortality rates have fallen and survival has improved for patients with non–small cell lung cancer.
Conference Coverage
Sintilimab scintillates in first-line nonsquamous NSCLC
Article
Artificial intelligence matches cancer genotypes to patient phenotypes
Conference Coverage
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
The mortality rate was 8% among patients who received immune checkpoint inhibitors, which is comparable with the overall mortality rate among...